[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexually-transmitted-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexually-transmitted-diseases":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,39,87,115,140,165,187,218,243,262,288,313,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100641410","clinical-evaluation-of-visby-medical-mens-sexual-health-test-100641410",false,"NCT07659808","Clinical Evaluation of Visby Medical Men's Sexual Health Test","Clinical Evaluation of Visby Medical Men's STI PCR Test for Detection of Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) From Urine in an at Home Setting","Inclusion Criteria:\n\n* Willing and able to provide written informed consent and\u002For assent as required by the reviewing IRB or IEC. Experimental Bill of Rights will also be documented for all study subjects enrolled in applicable states.\n* ≥14 years of age at the time of enrollment.\n* Subject has a penis at the time of enrollment.\n* Able to read and understand instructions provided for the study.\n* Willing and able to follow all study procedures, including performing self-collection of one urine sample, running the sample on a Visby test, and using the Visby App to interpret the test results.\n\nExclusion Criteria:\n\n* Have a medical condition, serious illness, or other circumstance that, in the investigator's judgment, could jeopardize the subject's safety, or could interfere with study procedures.\n* Have consumed oral or intramuscular or intravenous antibiotics, within 48 hours prior to enrollment.\n* The subject has urinated within the last one (1) hour prior to urine sample collection.\n* Have an in-dwelling catheter or practices intermittent catheterization for urinary drainage.\n* Have been previously enrolled in this study.",true,"MALE","14 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","This is a multi-center study in which the performance of the Visby Medical Men's Sexual Health Test is evaluated when run by male subjects of 14 years of age and older on self-collected first catch urine samples using the audio-visual instructions provided by the Visby App and\u002For written instructions provided by the printed User Instructions.",[25],"Sexually Transmitted Diseases","RECRUITING","2026-06-15",{"date":29,"type":30},"2026-06-22","ACTUAL",{"date":32,"type":30},"2026-02-05",{"date":34,"type":21},"2026-08",{"name":36,"class":37},"Visby Medical","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":64,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100509219","improving-alcohol-and-substance-use-care-access-outcome-equity-during-the-reproductive-years-100509219","NCT05910580","Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years","Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics","Inclusion Criteria:\n\n* Over the age of 18 years\n* U.S. residing\n* Have internet access (own a computer or smart phone)\n* Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments\n\nExclusion Criteria:\n\n* Not capable of communicating (reading, speaking, writing) in English or Spanish","ALL","18 Years",{"count":49,"type":21},400,"INTERVENTIONAL",[52],"NA","The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.\n\nThe main questions it aims to answer are:\n\n* Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing?\n* Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity?\n* Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)?\n\nParticipants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.\n\nResearchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.",[55,56,57,58,59,25,60,61,62,63],"Alcohol-Related Disorders","Substance-Related Disorders","Mental Health","Reproductive Health","Sexual Health","Contraception","Maternal Health","Pregnancy","Women's Health",[65,66,67,68,69,70,71,72,73,74,75,76],"Implementation Science","Mass Screening","Motivational Interviewing","Referral and Consultation","Quality of Health Care","Early Medical Intervention","Family Planning Services","Primary Health Care","Reproductive Health Services","Telemedicine","Preconception Care","Young Adult","2026-06-12",{"date":27,"type":30},{"date":80,"type":30},"2025-07-03",{"date":82,"type":21},"2027-05-31",{"name":84,"class":85},"Emory University","OTHER",4,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":16,"sex":17,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":50,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100556435","health-e-you-efficacy-trial-for-male-adolescents-100556435","NCT06525064","Health-E You Efficacy Trial for Male Adolescents","Health-E You\u002FSalud iTu: Pre-visit Mobile Health App for Male Adolescents to Promote Adolescent-centered Sexual & Reproductive Healthcare Receipt","Inclusion Criteria:\n\n* Assigned male sex at birth\n* Age 13 to 21 years old\n* English and\u002For Spanish as preferred language to read, listen, and converse\n* Self-reported engagement in vaginal and\u002For anal sex in the past 12 months\n* Access to phone or internet for follow-up study activities\n\nExclusion Criteria:\n\n* Aged 12 or younger or older than 21\n* Primary language other than English or Spanish\n* Not able to provide informed consent\n* Unable to communicate due to cognitive, mental, language, or other difficulties\n* Not sexually active, engaged in oral sex only, or more than 12 months have passed since last vaginal and\u002For anal sex.\n* Previous participation in a Health-E You study activity or the app","13 Years","21 Years",{"count":97,"type":21},2752,[52],"This study will involve evaluating Health-E You\u002FSalud ìTu™, a web-based, pre-visit mobile app designed to support adolescent male youth and his clinicians in discussing sexual and reproductive health (SRH) topics and care. It will test its efficacy among male patients in clinical settings using a stepped wedge cluster randomized controlled trial design.",[25,59,58],[102,103,104],"male adolescent","condom use","mhealth","2026-06-03",{"date":107,"type":30},"2026-06-05",{"date":109,"type":30},"2026-06-02",{"date":111,"type":21},"2027-12",{"name":113,"class":85},"Johns Hopkins University",8,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":46,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":50,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":38},"100560775","rigorous-evaluation-of-yes-and-know-a-fully-virtual-sexual-health-and-well-being-intervention-for-youth-100560775","NCT06581536","Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth","Rigorous Evaluation of Yes and Know, a Fully Virtual Intervention Integrating Group-based Education With Digital Tools to Improve Youth Sexual Health and Well-Being","Yes and Know","Inclusion Criteria:\n\n* Ages 14-19; and\n* English speaking.\n\nExclusion Criteria:\n\n\\- Anyone not meeting inclusion criteria.","19 Years",{"count":125,"type":21},1200,[52],"This study is a 2-arm cluster randomized controlled trial with approximately 1,200 youth aged 14-19 years to assess the effectiveness of Yes and Know, a sexual health education program. To be eligible, participants must be 14-19 years old and English-speaking. Those in the treatment arm will receive Yes and Know, a synchronous virtual program delivered over multiple sessions totaling nine hours, along with asynchronous online activities and resources. Those in the control arm will receive a similarly structured program focused on nutrition education. Participants will complete brief online surveys at baseline and at 3 and 12 months after the synchronous sessions. The study will assess the program's effectiveness in reducing the prevalence of unprotected sex among youth and improving short-term outcomes, such as knowledge of reproductive health and healthy relationships, self-efficacy, and the use of reproductive health services.",[129,25,130],"Pregnancy Related","Adolescent Behavior","2026-05-11",{"date":133,"type":30},"2026-05-14",{"date":135,"type":30},"2025-08-06",{"date":137,"type":21},"2027-12-31",{"name":139,"class":85},"ETR Associates",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":16,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":50,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":38},"100631418","doxi-rio-study-on-the-use-of-doxycycline-to-prevent-sexually-transmitted-infections-in-rio-de-janeiro-100631418","NCT07500415","Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro","Doxi-Rio: Pilot Implementation of Post-exposure Prophylaxis for Sexually Transmitted Infections With Doxycycline in Rio de Janeiro, Brazil","Inclusion Criteria:\n\n* Individuals assigned male at birth (cisgender or transgender men), transgender women, or travestis who have sex with men\n* Age ≥18 years\n* Living with HIV or currently using HIV pre-exposure prophylaxis (PrEP) for at least 6 months\n* History of at least one bacterial sexually transmitted infection (chlamydia, gonorrhea, or syphilis) in the past 12 months (laboratory-confirmed or self-reported)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to doxycycline or other tetracycline-class antibiotics\n* Current use of medications that may significantly interact with doxycycline or are contraindicated, including systemic retinoids, barbiturates, carbamazepine, or phenytoin",{"count":148,"type":21},200,[52],"The goal of this clinical trial is to learn if doxycycline post-exposure prophylaxis (doxy-PEP) can help prevent bacterial sexually transmitted infections (STIs) among sexual and gender minorities in Rio de Janeiro, Brazil, including men who have sex with men, transgender women, and travestis who are living with HIV or using HIV pre-exposure prophylaxis (PrEP). Bacterial STIs such as syphilis, gonorrhea, and chlamydia remain common in these populations, even with existing prevention strategies.\n\nThis study aims to answer the following questions: whether doxy-PEP can reduce the number of new STIs, whether it is safe and well tolerated, whether participants use it as recommended, and whether its use may contribute to antibiotic resistance or changes in the body's natural bacteria. Doxy-PEP involves taking a dose of doxycycline, an antibiotic, shortly after sexual activity to reduce the risk of acquiring STIs.\n\nParticipants will first receive information and counseling about doxy-PEP, including its possible benefits and risks, and will then choose whether or not to use this prevention strategy. Those who choose to use doxy-PEP will take doxycycline after sex as instructed and will be followed for up to 48 weeks, with clinic visits approximately every three months. During these visits, participants will be tested for STIs, monitored for side effects, and asked about medication use, sexual health, and overall well-being.\n\nResearchers will collect information on new STI diagnoses, safety, and how consistently participants use doxy-PEP. The study will also explore participants' experiences and perceptions of this strategy. The results of this study will help determine whether doxy-PEP is a practical and acceptable approach for STI prevention in Brazil and may inform future public health strategies.",[25,152,153,154,155],"Syphilis","Gonorrhea","Chlamydia Infections","HIV Infections","2026-03-24",{"date":158,"type":30},"2026-03-30",{"date":160,"type":30},"2025-10-28",{"date":162,"type":21},"2028-05",{"name":164,"class":85},"Oswaldo Cruz Foundation",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":16,"sex":46,"minAge":172,"maxAge":95,"enrollmentInfo":173,"targetDuration":4,"studyType":50,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":38},"100391122","health-information-technology-to-reduce-disparities-in-adolescent-health-outcomes-a-pragmatic-trial-100391122","NCT04372875","Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial","Leveraging Health Information Technology to Reduce Health Disparities in Adolescent Health Outcomes: A Patient-Centered Approach","Inclusion Criteria:\n\n* Adolescents aged 15-21 years seeking care in the emergency department\n\nExclusion Criteria:\n\n* Patients will be excluded if unable to understand English, are critically ill, cognitively impaired, or otherwise unable to provide consent for completion of the sexual health survey (SHS) and STI screening.","15 Years",{"count":174,"type":21},18500,[52],"We will compare differences in sexually transmitted infection (STI) detection rates between sexual health survey (SHS)-derived electronic clinical decision support (CDS) versus usual care (e.g. no provision of CDS) using an interrupted time series design. We hypothesize that population-based STI detection rates will be higher when SHS-derived electronic CDS is provided compared to usual care. Secondary analysis will include a comparison of STI detection rates by sexual risk strata (high risk vs. at risk) and race\u002Fethnicity.",[25],"2026-03-16",{"date":180,"type":30},"2026-03-18",{"date":182,"type":30},"2023-03-08",{"date":184,"type":21},"2027-01-15",{"name":186,"class":85},"Children's National Research Institute",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":16,"sex":46,"minAge":194,"maxAge":172,"enrollmentInfo":195,"targetDuration":4,"studyType":50,"phases":197,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":38},"100560640","evaluation-of-parent-toolkit-20-morehouse-family-health-study-100560640","NCT06579781","Evaluation of Parent Toolkit 2.0 (Morehouse Family Health Study)","Rigorous Evaluation of Morehouse School of Medicine's Parent Toolkit 2.0 Intervention (Morehouse Family Health Study)","Inclusion Criteria for Adult Participants:\n\n* 25 to 70 years old\n* Lives in an eligible zip code in Georgia\n* Parent or caregiver of 12- to 15-year-old child who wants to participate in this study with them\n* Lives with child at least 50% of the time\n\nExclusion Criteria for Adult Participants:\n\n* Lives in a home with a child who is already enrolled in this study\n* Raises child with an adult who is already enrolled in this study\n\nInclusion Criteria for Child Participants:\n\n* 12-15 years old\n* Lives with a parent or caregiver who wants to participate in this study with them\n* Able to complete surveys on own or with help of support person\n\nExclusion Criteria for Child Participants:\n\n\\- Does not have their own email address or phone number","12 Years",{"count":196,"type":21},2000,[52],"Child Trends will conduct a randomized control trial evaluation of Parent Toolkit 2.0, an innovative intervention for parents and caregivers of middle and high school students. Child Trends will collaborate with Morehouse School of Medicine and Tressa Tucker \\& Associates, LLC to implement and evaluate the program with 1,000 parent-teen pairs across Georgia. The program includes three components that will be delivered across a three-week period: (1) an online self-paced Parent Guide with information, tips, tools, and resources on adolescent health, including sexual health; (2) four videos modeling parent-teen communication around sex and contraception; and (3) two group-based sessions for parent participants to discuss program content and improve communication skills. The program aims to increase parent knowledge and parent-teen communication about adolescent health, sexual health, and relationships to help youth adopt health-promoting behaviors such as delaying sexual initiation and increasing contraceptive use.",[200,130,25,201,202],"Sexual Behavior","Contraception Behavior","Parent-Child Relations",[204,205,206,207,208],"teen pregnancy","STIs","parent-teen communication","parenting","adolescent sexual health","2025-04-25",{"date":211,"type":30},"2025-04-30",{"date":213,"type":30},"2024-10-21",{"date":215,"type":21},"2028-09-29",{"name":217,"class":85},"Child Trends",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":16,"sex":17,"minAge":47,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":50,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":242},"100516669","pharmacokinetic-characterization-of-a-single-200-mg-dose-of-doxycycline-in-post-exposure-prophylaxis-pep-of-sexually-transmitted-infections-in-different-biological-compartments-100516669","NCT06007534","Pharmacokinetic Characterization of a Single 200 mg Dose of Doxycycline in Post-exposure Prophylaxis (PEP) of Sexually Transmitted Infections in Different Biological Compartments","Caractérisation de la pharmacocinétique d'Une Dose Unique de 200 mg de Doxycycline en Prophylaxie Post-exposition (PEP) Des Infections Sexuellement Transmissibles Dans différents Compartiments Biologiques","DOXY-PK","Inclusion Criteria:\n\n* Adult male patient\n* Men who have Sex with Men (MSM) on PrEP or HIV-infected patients\n* Patients who have not taken doxycycline for at least 3 months\n* No symptoms of bacterial STI infection (chlamydia, gonorrhea, Mycoplasma genitalium or syphilis).\n* Documented history of bacterial STI infection within the past 12 months\n* Having had a risky intercourse within 24 hours and at the latest within 72 hours and for which a prescription of doxycycline in a single dose of 200 mg has been made within the framework of his usual follow-up.\n* Free, informed, written consent, signed by the person and the investigator at the latest on the day of inclusion and before any examination carried out within the framework of the study (article L1122-1-1 of the Public Health Code).\n* Person affiliated or benefiting from a social security system (article L1121-11 of the Public Health Code)\n\nExclusion Criteria:\n\n* Systemic treatment with retinoids (Acnetrait®, Procuta®, Curacné®, Contracné®, ....).\n* Treatment with enzyme-inducing anticonvulsants (carbamazepine, phenobarbital, phenytoin, etc.).\n* Known allergy to antibiotics of the tetracycline family.\n* Known allergy to one of the components of doxycycline tablets.\n* Documented esophageal injury\n* Ongoing treatment with doxycycline at the time of inclusion.\n* Person participating in another research study with an exclusion period still in progress at inclusion.\n* Persons under guardianship, conservatorship, or deprived of liberty by judicial or administrative decision.\n* Patients on State Medical Aid","100 Years",{"count":228,"type":21},25,[52],"Post-exposure prophylaxis (PEP) using doxycycline 200 mg within 24 hours of unprotected sexual intercourse to prevent sexually transmitted infections has demonstrated a reduction in the incidence of chlamydial and syphilis infections and syphilis infection by 70% and 73% in men who have sex with men (MSM) undergoing pre-exposure prophylaxis prophylaxis (PrEP) for HIV. Other studies are underway or in development on doxycycline prophylaxis for bacterial STIs, which are particularly common in this population. Monitoring adherence to PEP is of great interest in guaranteeing the effectiveness of this strategy and to be able to assess the uptake of PEP among PrEP users. Among the many methods for assessing adherence, measuring drug concentrations is a more accurate measure of adherence than self-reporting.\n\nThe therapeutic monitoring of doxycycline and the assessment of adherence have been described using plasma and hair samples, allowing estimation of intake over the last 3-4 days and 4 months, respectively. Nevertheless, these biological matrices present several limitations for application in clinical practice: reflecting the duration of exposure should be more in line with the frequency of visits (2 months), and the collection of hair samples may be difficult due to refusal or short hair. On the other hand, interpretation of the hair assay is limited by the degradation of doxycycline in this matrix, which could lead to underestimation of drug intake. By Therefore, new biological matrices are needed for more accurate assessment of doxycycline adherence in post-exposure prevention monitoring.\n\nThe objective is to evaluate the pharmacokinetics of doxycycline in plasma, whole blood, dried blood spots (DBS), urine and hair after a single dose of doxycycline in men using oral doxycycline for post-exposure prophylaxis of sexually transmitted infections (syphilis or Chlamydia trachomatis) and having sex with men.",[232,25,233],"Post-exposure Prophylaxis","Doxycycline","2024-09-13",{"date":236,"type":30},"2024-09-19",{"date":238,"type":30},"2023-10-25",{"date":209,"type":21},{"name":241,"class":85},"Assistance Publique - Hôpitaux de Paris",2,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":170,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":46,"minAge":172,"maxAge":95,"enrollmentInfo":249,"targetDuration":4,"studyType":50,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":38},"100391092","using-mobile-health-mhealth-to-improve-sti-treatment-adherence-among-adolescents-100391092","NCT04372485","Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents","Inclusion Criteria:\n\n* Adolescent patients seen in the Emergency Department who test positive for gonorrhea, chlamydia, or pelvic inflammatory disease and are prescribed outpatient antibiotic treatment.\n\nExclusion Criteria:\n\n* Patients will be excluded if they are unable to understand English, are critically ill, have cognitive impairment or if they do not have access to a cellular telephone with text messaging capabilities.",{"count":250,"type":21},270,[52],"We will conduct a randomized trial to compare differences in sexually transmitted infection (STI) treatment adherence between patients receiving text messages versus those receiving usual care (e.g. no text messages). We hypothesize that STI treatment adherence will be 20% higher among patients randomized to receipt of two-way text messaging services.",[25],"2024-08-19",{"date":256,"type":30},"2024-08-21",{"date":258,"type":30},"2024-06-03",{"date":260,"type":21},"2027-06",{"name":186,"class":85},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":16,"sex":46,"minAge":269,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":50,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":38},"100478906","our-healthbox---evaluating-interactive-dispensing-systems-for-low-barrier-access-to-hiv-testing-and-harm-reduction-100478906","NCT05516069","Our Healthbox - Evaluating Interactive Dispensing Systems for Low-Barrier Access to HIV Testing and Harm Reduction.","Reaching HIV Undiagnosed: Implementation and Evaluation of Interactive Dispensing Systems for Low-barrier Access to Rapid Testing and Harm Reduction Supplies With Linkage to Care for Marginalized and Hard-to-reach Populations in Canada.","Inclusion Criteria:\n\n* Age 16 years or older (except for Quebec: age 18 years or older)\n* Person living in Canada (Canadian resident)\n* Able to provide consent in English or French (via the machine screen)\n\nExclusion Criteria:\n\n* Does not meet all inclusion criteria","16 Years",{"count":271,"type":21},5000,[52],"When REACH Nexus at MAP Centre for Urban Solutions out of St. Michael's Hospital launched its signature program, I'm Ready in 2021, our goal was to democratize access to free HIV self-testing to reach the undiagnosed in Canada. The program, the first of its kind in Canada has been successfully rolling out 50,000 free, HIV self-tests and connecting participants via a mobile app on an iOS or Android smart phone to care.\n\nWhile this is an important milestone in improving access, REACH knows that more needs to be done. An estimated 20-30% of undiagnosed individuals do not have access to a phone to order the HIV self-tests, and many face multiple barriers to accessing healthcare and harm reduction support: chaotic life circumstances, addiction challenges, stigma and more.\n\nEveryone in Canada should have equitable access to the health care they need. But REACH knows that this is not the case.So, REACH is working hard to change this. hese ongoing barriers inspired us to continue creating innovative solutions, and launch our second signature program, Our Healthbox. Our Healthbox meets people where they are, with what they need for their health and well-being. This program is scaling up innovations in health technologies to reach undiagnosed individuals with HIV. These smart interactive vending machines will be strategically located across Canada. The goal is to reach people where they live to provide free and low barrier access to HIV self-testing kits, STBBI testing and other harm reduction supplies.\n\nParticipation in Our Healthbox, as with I'm Ready, also gives us the opportunity to collect important data that will continue to inform and guide REACH Nexus' work to grow and scale innovative health solutions across the country.",[275,276,277,25,278],"HIV","HIV Self-testing","Harm Reduction","Blood-Borne Infections","2024-07-17",{"date":281,"type":30},"2024-07-19",{"date":283,"type":30},"2023-01-23",{"date":285,"type":21},"2026-06-30",{"name":287,"class":85},"Unity Health Toronto",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":50,"phases":298,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":303,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100508178","phase-2-combination-therapy-between-doxycycline-pentoxifylline-and-nitazoxanide-in-sexually-active-men-100508178","NCT05897034","Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men","Clinical Study to Investigate the Effect of Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men","Inclusion Criteria:\n\n* Individuals aged \\> 18 years were eligible for participation if they had a diagnosis of untreated gonorrhea and chlamydia. The untreated status was defined as no antibiotic taken in the previous 28 days to treat gonorrhea and chlamydia.\n\nExclusion Criteria:\n\n* known contraindications or hypersensitivity to doxycycline, pentoxifylline, and nitazoxanide.\n\ngonorrhea with complications, such as pelvic inflammatory disease or epididymo-orchitis significant renal failure or hepatic failure.","60 Years",{"count":297,"type":21},100,[299,300],"PHASE2","PHASE3","Bacterial sexually transmitted infections (STIs) have been steadily increasing in gay, bisexual, and other men who have sex with men (MSM) over the past 2 decades. While that trend started prior to the introduction of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in 2012, HIV PrEP has been associated with increases in sexual contacts and decreases in condom use with an resultant acceleration in the increase of bacterial STIs such as gonorrhea, syphilis, and chlamydia.",[25],"NOT_YET_RECRUITING","2023-06-08",{"date":306,"type":30},"2023-06-12",{"date":308,"type":21},"2023-06-20",{"date":310,"type":21},"2028-06-20",{"name":312,"class":85},"Tanta University",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":16,"sex":46,"minAge":172,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":50,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":86},"100428187","comparing-mobile-health-strategies-to-improve-pre-exposure-prophylaxis-use-prep-for-hiv-prevention-100428187","NCT04855773","Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention","PCORI PrEP","Inclusion Criteria:\n\n* Self-identifies as a cisgender man, transgender man (assigned female at birth, trans-masculine spectrum), or transgender woman (assigned male sex at birth, trans-feminine spectrum)\n* Report sex with a cisgender man or transgender woman or any individual assigned male sex at birth in the past 12 months\n* Age 15 years or older\n* Willing and able to provide written informed consent\n* Owns an iOS or Android mobile phone and able to access the internet and send and receive text messages\n* Able to understand, read, and speak English or Spanish\n* Newly initiated PrEP or currently on PrEP and at risk for PrEP discontinuation based on at least one of the following:\n\n  * Initiated PrEP within the past 6 months, or\n  * Has any of the following risk factors for PrEP discontinuation: missed clinic visits; age \\\u003C 30; African-American or Latino; transgender gender identity; or self-reported illicit substance use\n\nExclusion Criteria:\n\n* Currently enrolled in another PrEP intervention study\n* Unable to complete 12 month study participation\n* Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.",{"count":321,"type":21},300,[52],"The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help prevent HIV infection.",[155,25],[326,327,328,329],"Pre-exposure Prophylaxis (PrEP)","HIV Prevention","Mobile health (mHealth)","Medication adherence","2022-09-27",{"date":332,"type":30},"2022-09-28",{"date":334,"type":30},"2021-07-21",{"date":336,"type":21},"2023-08",{"name":338,"class":85},"Public Health Foundation Enterprises, Inc.",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":226,"enrollmentInfo":347,"targetDuration":349,"studyType":22,"phases":4,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":38},"100464312","vienna-hiv-infection-via-sex-study-100464312","NCT05326061","Vienna HIV Infection Via Sex Study","Characterization of Patients at High Risk for the Acquisition of Sexually Transmitted Infection With the Human Immunodeficiency Virus (HIV) - a Clinical Study","HIVEX","Inclusion Criteria:\n\n1. High risk for acquiring HIV defined as followed: HIV-negative MSM and transgender individuals who (i) do not use condoms consistently with casual partners and\u002For with HIV-positive partners who are not on treatment and\u002For (ii) recently acquired an STI and\u002For (iii) recently used PEP and\u002For (iv) frequently engage in 'chemsex'.\n2. Age \\>18 years and \\\u003C100 years.\n3. Written informed consent for this registry study.\n\nExclusion Criteria:\n\n1\\. Withdrawal of the written informed consent.",{"count":348,"type":21},500,"5 Years","The main objective of this prospective observational cohort study is to investigate the epidemiology, the risk factors and ultimately the incidence of novel HIV infections among individuals at high risk for acquiring HIV via sex practices.",[155,352,25,153,353,152],"HIV Pre-Exposure Prophylaxis","Chlamydia","2022-04-06",{"date":356,"type":30},"2022-04-13",{"date":358,"type":30},"2020-07-01",{"date":360,"type":21},"2030-12",{"name":362,"class":85},"Medical University of Vienna"]